Computational targeting of allosteric site of MEK1 by quinoline‐based molecules

Abstract

MEK1 is an attractive target due to its role in selective extracellular‐signal‐regulated kinase phosphorylation, which plays a pivotal role in regulating cell proliferation. Another benefit of targeting the MEK protein is its unique hydrophobic pocket that can accommodate highly selective allosteric inhibitors. To date, various MEK1 inhibitors have reached clinical trials against several cancers, but they were discarded due to their severe toxicity and low efficacy. Thus, the development of allosteric inhibitors for MEK1 is the demand of the hour. In this in‐silico study, molecular docking, long‐term molecular dynamics (5 µs), and molecular mechanics Poisson–Boltzmann surface area analysis were undertaken to address the potential of quinolines as allosteric inhibitors. We selected four reference MEK1 inhibitors for the comparative analysis. The drug‐likeness and toxicity of these molecules were also examined based on their ADMET and Toxicity Prediction by Komputer Assisted Technology profiles. The outcome of the analysis revealed that the quinolines (4m, 4o, 4s, and 4n) exhibited better stability and binding affinity while being nontoxic compared to reference inhibitors. We have reached the conclusion that these quinoline molecules could be checked by experimental studies to validate their use as allosteric inhibitors against MEK1.

Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors

“…Computer-aided drug design (CADD) involves high-throughput screening of selective ligands to agonize or antagonize target structures [7,8]. CADD relies on the assumption that candidate compounds have affinity to protein targets with minimum side effects while having sufficient absorption, distribution, metabolism and excretion (ADME) properties [9,10]. Some promising malaria compounds that have recently progressed to clinical evaluation include KAE609 [11], M5717 [12], MMV390048 [13] and others [14].…”

Identification of potential inhibitors, conformational dynamics, and mechanistic insights into mutant Kirsten rat sarcoma virus (G13D) driven cancers

“…12 Several research studies have utilized contemporary computational techniques to identify the small molecule inhibitors and structural mechanisms that help experimental researchers to test the drugs in vivo and in vitro, for targeted therapy. [13][14][15] We integrated pharmacophore modeling with many such approaches for mutationspecific K-Ras drug development to determine the compounds targeting K-Ras G13D. This was done by generating pharmacophore hypotheses utilizing the recognized inhibitory compounds to generate a model with all the characteristics needed for the prospective drug.…”

“…A recent study identified several FDA‐approved inhibitors targeting G12C and G12D K‐Ras models using pharmacophore modeling and a drug‐repurpose approach 12 . Several research studies have utilized contemporary computational techniques to identify the small molecule inhibitors and structural mechanisms that help experimental researchers to test the drugs in vivo and in vitro, for targeted therapy 13–15 . We integrated pharmacophore modeling with many such approaches for mutation‐specific K‐Ras drug development to determine the compounds targeting K‐Ras G13D.…”

Novel benzylidene benzofuranone analogues as potential anticancer agents: design, synthesis and in vitro evaluation based on CDK2 inhibition assays

“…Instead, these restrictions have supported researchers to have better insight to understand the molecular processes that underlie the onset of different stages of cancer (Jayashree et al 2015 ). In the light of this, much efforts are being made so as to identify and validate newer targets in cancer biology (Singh et al 2022 ). Some of the anticancer targets that are presently identified in the clinical set up includes tyrosine kinase (Bhardwaj et al 2020 ), Farnesyl transferases, histone deacetylases, aromatase and cyclin-dependent kinases (CDKs).…”